Veradigm | MDRX - Sales Revenues

Stock Price
4.31
Daily Change
-0.19 -4.22%
Monthly
-6.30%
Yearly
-15.49%
Q1 Forecast
7.75

Veradigm reported $151.9M in Sales Revenues for its fiscal quarter ending in September of 2022.





Sales Change Date
Alcidion AUD 23.15M 5.51M Jun/2025
Ambu A/S DKK 1.56B 90M Dec/2025
Amplifon EUR 563.3M 29.55M Sep/2025
Cardinal Health USD 65.63B 1.63B Dec/2025
Centene USD 49.73B 40M Dec/2025
Charles River Laboratories USD 994.2M 5.8M Dec/2025
Cigna USD 72.47B 2.77B Dec/2025
Computer Programs Systems USD 83.83M 900K Sep/2024
Convatec Group USD 1.18B 0 Jun/2025
CVS Health USD 105.7B 2.8B Dec/2025
Diasorin EUR 280M 26M Sep/2025
Elevance Health USD 49.3B 790M Dec/2025
General Electric Aerospace USD 11.87B 560M Dec/2025
Gulf Medical Proj AED 185.37M 5.32M Jun/2025
Humana USD 32.52B 130M Dec/2025
IQVIA Holdings USD 4.36B 260M Dec/2025
Laboratory Of America USD 3.52B 40M Dec/2025
Maximus USD 1.35B 30M Dec/2025
McKesson USD 106.16B 3.01B Dec/2025
Med Life RON 787.96M 8.36M Sep/2025
Molina Healthcare USD 11.38B 100M Dec/2025
Omnicell USD 314M 3.37M Dec/2025
Oriola-kd EUR 463.3M 30.6M Sep/2025
Owens Minor USD 697.26M 15.36M Sep/2025
Quest Diagnostics USD 2.81B 10M Dec/2025
Rede D'or Sao Luiz BRL 14.6B 480M Sep/2025
Siemens Healthineers EUR 5.4B 920M Dec/2025
Sonova Holding CHF 1.82B 216.8M Dec/2025
Supermax Corporation Bhd MYR 205.56M 50.82M Sep/2025
UnitedHealth USD 113.2B 0 Dec/2025
Veeva Systems USD 811.24M 22.15M Sep/2025
Veradigm USD 151.9M 1M Sep/2022
Xerox USD 2.03B 70M Dec/2025